Program
AB-101
Also written as “zabalafin”.
Its studies are mostly in Hepatitis B, Chronic · Lymphoma, Non-Hodgkin · Lupus Nephritis · Hodgkin Disease · Dermatitis, Atopic, led by 5 companies.
Drug pageAB-101: every studyMany companies study it; this page follows only the 6 they lead. All 7 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Artiva Biotherapeutics | 21 open or running | phase 2since Dec 4, 2020 | Dec 4, 2020 | Aug 2027phase 1 · NCT06265220 |
| Affimedits history only | 10 open or running | phase 2since May 19, 2023 | May 19, 2023 | none ahead |
| Alphyn Biologicsits history only | 11 open or running | phase 2since Feb 27, 2025 | Feb 27, 2025 | none ahead |
| Applied Biologyits history only | 10 open or running | early phase 1since Jul 8, 2018 | Jul 8, 2018 | none ahead |
| Arbutus Biopharmaits history only | 10 open or running | phase 1since Jul 14, 2023 | Jul 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Artiva Biotherapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 4, 2020First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT04673617 · 45 enrolled · United States
- Feb 9, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06265220 · 51 enrolled · United States
Ahead
- Aug 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06265220
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Artiva Biotherapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06265220Lupus Erythematosus, Systemic · United States | 1 | Active, not recruiting | Aug 2027 | 51 |
| NCT04673617Lymphoma, Non-Hodgkin · United States | 2 | Completed | Oct 6, 2025 | 45 |
How it is read
Names in the registry
- “AB-101”, 5 entries
- “zabalafin”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Lupus Nephritis, 1 study
- Hodgkin Disease, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.